Neon Therapeutics Obtains $55,000,000 Series A Funding Round

  • Feed Type
  • Date
    10/2/2015
  • Company Name
    Neon Therapeutics
  • Mailing Address
    215 First Street Cambridge, MA 02142 USA
  • Company Description
    We have assembled a team of world experts in cancer immunotherapy to develop therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. Our programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need.
  • Website
    http://www.neontherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $55,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The contributions from world-leading experts in core scientific advances in neoantigen biology have paved the way for the founding of Neon Therapeutics, and the company plans to work closely with them moving forward to bring new therapies to patients.
  • M&A Terms
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Access Industries
  • Venture Investor
    Clal Biotechnology Industries

Trending on Xconomy